Tagged with Novo Nordisk,

Switzerland Diabetes is well managed in Switzerland’s patient-centric healthcare system, yet with new data showing Novo Nordisk’s GLP-1 has strong cardiovascular benefits, the company is working to drive a change in treatment standards. Switzerland has been recognized as the most innovative country in the world, and is known to have a…

Pharma 2016 has been a great year for PharmaBoardroom, with interviews from global CEOs and ministers, groundbreaking country reports on some of the world’s key pharma markets, and insightful articles which get to the heart of the sector’s key issues. Stay tuned in 2017 for more of the same! INTERVIEWS OF…

Singapore Peter Ulvskjold, the Corporate Vice President of International Operations in Southeast Asia, highlights the challenges in the region facing diabetics and how Novo Nordisk is working to close the gaps in access and education for insulin in the region. You have been overseeing South East Asia for about a year…

Pharma A native of Serbia, Aleksandar Ciric provides his first impressions of the Slovak market and business atmosphere, emphasizing the transparency and market accessibility. His current priority at Novo Nordisk is to develop the local organization by developing its people in order to maintain a competitive edge. After eight months in Slovakia,…

Global In part two of an exclusive interview, Novo Nordisk’s Maziar Mike Doustdar expands on the potential of emerging markets to foster innovation, managing risk, local partnerships, and the company’s unwavering commitment to fighting diabetes.   To what extent can immature markets become sources of innovation in healthcare technologies? Does limited infrastructure not…

Global In part one of an exclusive interview (part two here), Novo Nordisk’s Maziar Mike Doustdar explains the significance of the 141 countries in the company’s IO region to global operations and the varying strategies for success in these geographies.   Novo Nordisk’s International Operations (IO) region groups together some 141…

Pharma Novo Nordisk Hungary GM Zsolt Jozsa highlights the growing prevalence of diabetes in Hungary, the gap in treatment options that the company is striving to close with Tresiba and Xultophy, and the limitations of Hungary’s regulatory framework. Zsolt, you took over the helm of Novo Nordisk Hungary in 2012, after…

Pharma Dr. Costas Piliounis discusses the importance of containing diabetes, the dampening effects budget ceilings have on companies’ performance and growth potential, as well as the positive influence which changes currently being implemented in the regulatory system will have on the industry moving forward.   Dr. Piliounis, to start off, you…

Pharma In Egypt’s diverse marketplace, Novo Nordisk is bringing care to patients across the country with a range of products ranging from affordable established insulin to their most recent generation of innovative products. At the same time, they are investing in localizing production of insulin in Egypt and encouraging best practices in diabetes…

Holland In a market under strong pressures to contain costs, launching innovative products in a crowded market can be a challenge. Novo Nordisk GM Sanne Groenemeijer believes his organization’s willingness to try various solutions has helped them to maintain their dominant position as the market leader in diabetes. Since you took…

Roche Miguel Centeno, general manager and head of Roche Diabetes Care in Puerto Rico, highlights the affiliate’s strong manufacturing performance in the area of diabetes care (DC) blood glucose test strips above its competitors.   Can you provide us with an overview of the current state of the medical device and…

Novo Nordisk Novo Nordisk Turkey has taken a degree of leadership by working to facilitate and encourage cooperation and collaboration between different stakeholders in the diabetes management ecosystem. For general manager Şebnem Avşar Tuna, developing stronger lines of communication with regulators and payers is the top priority going forward.   Following your…